Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,101–1,200 of 3,636
Wang, X., Qiu, M., Cheng, Z., Ji, X., Chen, J., Hong, Z., Tang, Y., Huang, Z., Su, G., Wang, G., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033669 · Cited by 19
“…approved PCSK9 monoclonal antibodies (evolocumab and alirocumab) have been demonstrated to reduce LDL-C levels by 50% to 70%, 2 as well as the risk of major adverse cardiovascular events by 15% compared with placebo, 5,6 suggesting additional cardiovascular benefits from a greater LDL-C reduction.”
BackgroundLipid Lowering Therapy Utilization and Lipid Goal Attainment in Women
van Oortmerssen, J. A. E., Mulder, J. W. C. M., van der Bijl, M. F., Mijnster, R. J. M., Kavousi, M., & van Lennep, J. E. R. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01275-1 · Cited by 20
“Both PCSK9 mAbs have a favorable safety profile and no sex differences were observed in their association with cardiovascular endpoints [63, 64, 67, 69].”
Zimerman, A., Kunzler, A. L. F., Weber, B., Ran, X., Murphy, S. A., Wang, H., Honarpour, N., KEECH, A. C., Sever, P., Sabatine, M. S., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072756 · Cited by 22
Residual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 31
Владиславович, Е. М., Tmoyan, N. A., Afanasieva, O. I., Afanasieva, M. I., & Pokrovsky, S. N. (2021) · Biomolecules · doi:10.3390/biom11020257 · Cited by 16
“Recent landmark randomized trials have shown a decrease in cardiovascular events (CVE) with high-intensity lipid-lowering therapy and substantial reduction of LDL-C level [1,2].”
BackgroundZhou, Y., Chen, W., Lu, M., & Wang, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.617249 · Cited by 18
“Each study was evaluated on three broad criteria: (1) subject selection; (2) comparability of the subjects; and (3) ascertainment of the outcome or exposure.”
BackgroundMethodInfluentialSetny, M., Jankowski, P., Krzykwa, A., Kamiński, K. A., Gąsior, Z., Haberka, M., Czarnecka, D., Pająk, A., Kozieł, P., Szóstak-Janiak, K., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122594 · Cited by 16
“, the combination of statins and ezetimibe [17,18], as well as in the use of PCSK9 inhibitors [19,20], which are hardly available due to their price.”
BackgroundPotent Lys Patch-Containing Stapled Peptides Targeting PCSK9
Bourbiaux, K., Legrand, B., Verdié, P., Mallart, S., Manette, G., Minoletti, C., Stepp, J. D., Prigent, P., Bail, J.-C. L., Gauzy, L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02051 · Cited by 17
Zhao, Y., Yang, S., & Wu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794417 · Cited by 16
“cardiovascular ischemic events, such as myocardial infarction, stroke, and death still reoccur every year after the rational use of drugs (Eikelboom et al., 2017; Sabatine et al., 2017; Schwartz et al., 2018).”
BackgroundEffect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
Gao, F., Li, Y. P., Ma, X., Wang, Z. J., Shi, D. M., & Zhou, Y. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907662 · Cited by 16
“As a novel lipid lowering agent, PCSK9 inhibitors have been demonstrated with significantly reduction in LDL cholesterol, lipoprotein(a) [Lp(a)] and cardiovascular events (10, 11).”
BackgroundGouni‐Berthold, I., Schwarz, J., & Berthold, H. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01053-3 · Cited by 19
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 80
Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 29
Bär, S., Kavaliauskaite, R., Otsuka, T., Ueki, Y., Häner, J. D., Siontis, G. C. M., Stortecky, S., Shibutani, H., Temperli, F., Kaiser, C. A., et al. (2023) · EuroIntervention · doi:10.4244/eij-d-23-00201 · Cited by 18
(2023) · PubMed Central · Cited by 16
Deng, Y., Ma, Y., Yubin, Z., Jiapei, G., Xun, S., He, S., Li, Z., & Zhang, J. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131775 · Cited by 19
Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients
Gaiţă, L., Timar, B., Timar, R. Z., Fras, Z., Gaiță, D. I., & Banach, M. (2024) · Pharmaceuticals · doi:10.3390/ph17020219 · Cited by 33
“…in studies such as ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) with alirocumab and FOURIER (the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) with evolocumab [42–44].”
MethodRexhaj, E., Bär, S., Soria, R., Ueki, Y., Häner, J. D., Otsuka, T., Kavaliauskaite, R., Siontis, G. C. M., Stortecky, S., Shibutani, H., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117504 · Cited by 21
Zahger, D., Schwartz, G. G., Du, W., Szarek, M. J., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Jukema, J. W., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.035 · Cited by 22
Self-citationSpitthöver, R., Röseler, T., Julius, U., Heigl, F., Schettler, V. J. J., Kühn, R., Leebmann, J., Raabe, A., Knittel, M., Schürfeld, C., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21695 · Cited by 16
Cordero, A., Fácila, L., Rodríguez‐Mañero, M., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.03.019 · Cited by 16
Pinto, R. D., Grassi, D., Properzi, G., Desideri, G., & Ferri, C. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00323-7 · Cited by 17
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 18
Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors
Luca, L. D., Corsini, A., Uguccioni, M., & Colivicchi, F. (2020) · Kardiologia Polska · doi:10.33963/kp.15529 · Cited by 18
“Both trials enrolled high-risk groups with established ASCVD and LDL-C levels ≥ 70 mg/dL on optimal statin therapy [50,51].”
BackgroundMethodResultInfluentialHit or miss: the new cholesterol targets
DuBroff, R. J., Malhotra, A., & de Lorgeril, M. (2020) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111413 · Cited by 17
Chaudhary, S., Chaudhary, N., Ghewade, B., et al. (2020) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2020.121710 · Cited by 16
Treatment With Cardiovascular Medications: Prognosis in Patients With Myocardial Injury
Kadesjö, E., Roos, A., Siddiqui, A. J., Sartipy, U., & Holzmann, M. J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017239 · Cited by 19
Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans
Derington, C. G., Colantonio, L. D., Herrick, J. S., Cook, J. R., King, J. B., Rosenson, R. S., Poudel, B., Monda, K. L., Návar, A. M., Mues, K. E., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019254 · Cited by 18
“Two cohorts of veterans were analyzed: (1) atherosclerotic cardiovascular disease, with a most recent low- density lipoprotein cholesterol (LDL- C) ≥70 mg/dL; and (2) severe hypercholesterolemia (ie, familial hypercholesterolemia or any prior LDL- C ≥190 mg/dL, with most recent LDL- C ≥100 mg/dL).”
BackgroundMethodInfluentialChallenges in Optimizing Lipid Management in Women
Peterson, K., Kaur, G., Gianos, E., Mookherjee, S., Poli, K. A., Sidhu, M. S., & Lyubarova, R. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07273-0 · Cited by 20
Sulman, D., Zeitouni, M., Silvain, J., Kernéis, M., Guedeney, P., Barthélémy, O., Brugier, D., Sabouret, P. F., Lattuca, B., Mertens, E., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac021 · Cited by 16
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
“While treatment awareness might still play a significant role in this matter [91,94], the novel lipid-lowering agents, alone or as combination therapy with statins or ezetimibe, provide highly effective and well-tolerated treatment options to achieve sufficient LDL-C reduction below treatment targets [11,13,14,95].”
BackgroundMethodWisløff, T. F., Mundal, L. J., Retterstøl, K., Igland, J., & Kristiansen, I. S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.900 · Cited by 15
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 16
Bempedoic Acid: A New Drug for an Old Problem
Nguyen, D., Du, N., Sulaica, E. M., & Wanat, M. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020941083 · Cited by 18
Wong, N. D., Fan, W., Philip, S., Granowitz, C. B., & Toth, P. P. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.015 · Cited by 16
Michos, E. D., & Martin, S. S. (2019) · Circulation · doi:10.1161/circulationaha.119.044275 · Cited by 17
Women and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
“1016/S01406736(19)31149-3; PMID: 31189511.”
Self-citationPCSK9 in T-cell function and the immune response
Wang, Y., Fang, X., Liu, J., Lv, X., Lu, K., Lu, Y., & Jiang, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00712-8 · Cited by 19
Oral PCSK9 Inhibitors: Will They Work?
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01299-7 · Cited by 17
“…to reduce cardiovascular events [ 8 ] Inhibitors of proprotein conver-tase subtilisin/kexin type 9 (PCSK9), a key regulator of circulating LDL-C levels, can be added to ongoing lipid-lowering therapy to achieve a greater reduction in LDL-C levels and further reduce cardiovascular risk [9, 10].”
Low LDL-Cholesterol and Hemorrhagic Risk: Mechanistic Insights and Clinical Perspectives
Siniscalchi, C., Basaglia, M., Meschi, T., Imbalzano, E., Bernardi, F. F., Perrella, A., Trama, U., Passannanti, A., Micco, P. D., & Schiano, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125612 · Cited by 17
“While they do not directly inhibit cholesterol biosynthesis, the resulting depletion of plasma LDL may limit the cholesterol reservoir available for membrane maintenance, particularly in cells with limited capacity for de novo synthesis [14–16].”
Bempedoic Acid for Lowering LDL Cholesterol
Honigberg, M. C., & Natarajan, P. (2019) · JAMA · doi:10.1001/jama.2019.16598 · Cited by 16
PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability
Enkhmaa, B., Kim, K., Zhang, W., Prakash, N., Truax, K., Anuurad, E., & Berglund, L. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa073 · Cited by 16
PCSK9 monoclonal antibodies: An overview
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Heart Views · doi:10.4103/heartviews.heartviews_20_20 · Cited by 20
“[7,58] The ODYSSEY OUTCOMES[59] trial (2018) was a multicenter, double-blind, randomized control trial that investigated the effect of alirocumab (75 mg or 150 mg Q2W) on top of statin therapy on CV events.”
BackgroundMethodInfluentialEffect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis
Masson, W. M., Lobo, M., Cobo, A. L., & Molinero, G. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.002 · Cited by 17
Patel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 24
Wang, B., Chen, S., Liu, J., Liang, Y., Meng, L., Yan, X., Huang, H., Chen, G., Huang, Z., Xu, D., et al. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02375-1 · Cited by 14
Irewall, A.-L., Ulvenstam, A., Graipe, A., Ögren, J., & Mooe, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-94892-0 · Cited by 16
Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Moustafa, B., & Testai, F. D. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106057 · Cited by 19
Барбараш, О. Л., Komarov, A. L., Панченко, Е. П., Староверов, И. И., Shakhnovich, R. M., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-4-6-59 · Cited by 16
Abushanab, D., Al‐Badriyeh, D., Marquina, C., Bailey, C., Jaam, M. J., Liew, D., & Ademi, Z. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101211 · Cited by 17
East, C. A., Bass, K., Mehta, A. N., Rahimighazikalayed, G., Zurawski, S., & Bottiglieri, T. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100483 · Cited by 18
“Studies of PCSK9 inhibitors in patients at a high risk of atherosclerotic events have shown benefit.(9,10) However, alirocumab has not been studied for its effects on LDL-C, inflammatory biomarkers, and metabolomics in patients receiving maintenance dialysis.”
BackgroundMethodHaegele, M., Djurdjevic, A., Jordan, F., Liu, Y., Mildner, L., Frey, S., Strebel, I., Clerc, O. F., Burkard, T., & Pfister, O. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237057 · Cited by 17
“Recent advances in lipid-lowering therapies including the use of high-potent statins and their combination with non-statin medications such as ezetimibe and PCSK9 inhibitors resulted in LDL-C reduction of 50–80% and improved clinical outcomes [4,5].”
BackgroundSchrör, K., Trenk, D., & Verheugt, F. W. A. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1758654 · Cited by 19
Trier, T. J. V., Snaterse, M., Hageman, S. H. J., ter Hoeve, N., Sunamura, M., van Charante, E. P. M., Galenkamp, H., Deckers, J. W., Martens, F. M. A. C., Visseren, F. L. J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad038 · Cited by 21
Statin Intolerance: an Overview of US and International Guidance
Cheeley, M. K., Clegg, K., Lockridge, C., Schubert, T. J., & Jones, L. K. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01124-z · Cited by 21
Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
LaFratte, C., Peasah, S. K., Huang, Y., Hall, D. L., Patel, U. B., & Good, C. B. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029707 · Cited by 15
Duell, P. B., Banach, M., Catapano, A. L., Laufs, U., Mancini, G. B. J., Ray, K. K., Broestl, C., Zhang, Y., Lei, L., & Goldberg, A. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.12.005 · Cited by 21
Sucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071882 · Cited by 24
“The monoclonal antibodies alirocumab and evolocumab, which are administered subcutaneously once or twice a month, have been shown to selectively inhibit the PCSK9 protein [32–34].”
BackgroundManagement of dyslipidemia in coronary artery disease: the present and the future
Dimitriadis, K. S., Theofilis, P., Iliakis, P., Pyrpyris, N., Dri, E., Sakalidis, A., Σουλαϊδόπουλος, Σ., Tsioufis, P., Fragkoulis, C., Chrysohoou, C. A., et al. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001375 · Cited by 23
“Odyssey outcomes was a randomized, double-blind, placebo-controlled trial that studied the effect of another PCSK9 inhibitor on LDL-C levels’ lowering and cardiovascular risk reduction [14].”
Bay, B., Vogel, B., Sharma, R., Sartori, S., Leone, P. P., Nathani, M., Oliva, A., Smith, K. F., Hooda, A., Sweeny, J. M., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02471-w · Cited by 16
“However, a high residual risk for major adverse cardiovascular events (MACE) of 5% per year has been reported in contemporary studies even after adherence to guideline directed medical therapy [3–5].”
PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
Grejtáková, D., Boroňová, I., Bernasovská, J., & Bellosta, S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07599-5 · Cited by 25
Dimitriadis, K. S., Pyrpyris, N., Iliakis, P., Beneki, E., Adamopoulou, E., Papanikolaou, A., Konstantinidis, D., Fragkoulis, C., Κόλλιας, Α., Aznaouridis, K. A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175040 · Cited by 17
Long-Term Lipid Lowering With Evolocumab in Older Individuals
Said, S. A., O’Donoghue, M. L., Ran, X., Murphy, S. A., Atar, D., KEECH, A. C., Flores‐Arredondo, J. H., Wang, B., Sabatine, M. S., & Giugliano, R. P. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.019 · Cited by 17
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
Julius, U., Tselmin, S., Schatz, U., Fischer, S., & Bornstein, S. R. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00099-z · Cited by 16
An updated review of lipid‐modifying therapy
Simons, L. A. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50142 · Cited by 18
Kristiansen, O., Vethe, N. T., Fagerland, M. W., Bergan, S., Munkhaugen, J., & Husebye, E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14122 · Cited by 15
Lipid management beyond the guidelines
Robinson, J. G. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.004 · Cited by 16
Quiroga, B., Ramos, P. M., & Chiva, V. Á. (2020) · Nefrología · doi:10.1016/j.nefro.2020.04.020 · Cited by 18
A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?
Strandberg, T. E., Libby, P., & Kovanen, P. T. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa131 · Cited by 15
Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides
Harbour, V., Casillas, C., Siddiqui, Z., Sarkar, B., Sanyal, S., Nguyen, P. K., Kim, K. K., Roy, A., Iglesias-Montoro, P., Patel, S., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01229 · Cited by 16
Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis
Sagris, D., Ntaios, G., Georgiopoulos, G. A., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.11.021 · Cited by 15
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
Radkhah, N., Shab‐Bidar, S., Zarezadeh, M., Safaeiyan, A., & Barzegar, A. (2021) · Journal of Cardiovascular and Thoracic Research · doi:10.34172/jcvtr.2021.21 · Cited by 15
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 16
Statin intolerance and new lipid-lowering treatments
Mesi, O., Lin, C., Ahmed, H. M., & Cho, L. S. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20165 · Cited by 17
“Monoclonal antibody PCSK9 inhibitors belong to a novel class of lipid-lowering therapy that have been reported to reduce LDL-C concentrations by up to 60% 19,30–33 and reduce the risk of cardiovascular events.”
Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?
Siostrzonek, P., Brath, H., Zweiker, R., Drexel, H., Hoelzl, R., Hemetsberger, M., & Ray, K. K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01978-w · Cited by 15
Kim, J. Y., Choi, J., Kim, S. G., & Kim, N. H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01466-z · Cited by 15
Marchis, G. M. D., Dittrich, T. D., Malik, R., Zietz, A. V., Kriemler, L. F., Ference, B. A., Dichgans, M., & Georgakis, M. K. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.09.007 · Cited by 15
The year in cardiology 2018: acute coronary syndromes
Widimský, P., Crea, F., Binder, R. K., & Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy904 · Cited by 17
Evidence-Based Cardiovascular Risk Management in Diabetes
Mooradian, A. D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00336-6 · Cited by 16
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 17
“9 (PCSK9) inhibitors, alirocumab and evolocumab [6,7], to”
BackgroundCho, K. H., & Hong, Y. J. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.140 · Cited by 17
Secondary prevention after CABG: do new agents change the paradigm?
Paquin, A., Poirier, P., Beaudoin, J., & Piché, M. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000783 · Cited by 16
“LIPID-LOWERING AGENTS: NEW EVIDENCE FROM CARDIOVASCULAR OUTCOME TRIALS PCSK9-targeted therapy Clinical trials have shown that a nonstatin agent combined with maximally tolerated statin dose, irrespective of baseline LDL-cholesterol levels, can further reduce recurrent cardiovascular events [22,23].”
BackgroundMethodResultInfluentialTomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
“They were shown to be effective in reducing ASCVD events with evolocumab in the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial [10] and with alirocumab in ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome with Alirocu…”
Plaque Stabilization and Regression, from Mechanisms to Surveillance and Clinical Strategies
Zhang, X., Feng, H.-H., Han, Y., Yuan, X.-H., Jiang, M., Wang, W., & Gao, L. (2024) · Reviews in cardiovascular medicine · doi:10.31083/j.rcm2512459 · Cited by 14
Mohammadnia, N., Wesselink, B. E., Bax, W. A., Nidorf, S. M., Mosterd, A., Fiolet, A. T. L., Cetinyurek‐Yavuz, A., Thompson, P. L., Bangdiwala, S. I., Eikelboom, J. W., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038687 · Cited by 18
“14,15 16 Finally, because this secondary LoDoCo2 analysis was not prespecified, our findings should be interpreted as hypothesis generating.”
Brandts, J., Barkas, F., Bacquer, D. D., Jennings, C. S., Backer, G. D., Kotseva, K., Rydén, L., Lip, G. Y. H., Erlund, I., Ganly, S., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf388 · Cited by 17
Jones, L. K., East, C. A., Ganda, O. P., & Gionfriddo, M. R. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037530 · Cited by 17
“…lowering, the addition of nonstatin LLTs such as ezetimibe or bempedoic acid or PCSK9-directed therapies (anti-PCSK9 monoclonal antibodies or inclisiran) is recommended by lipid management guidelines 4,5 and can further reduce LDL-C levels by ≈20%, 68 36%, 69 and 50% to 60%, 70–72 respectively.”
Bosco, G., Barbagallo, F. D. G., Marco, M. D., Scilletta, S., Miano, N., Pistritto, C., Tiralongo, M., Stefano, C. D., Pennisi, G., Francesco, E. M. D., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07432-z · Cited by 18
“Evidence from phase III trials with PCSK9 monoclonal antibodies (PCSK9-mAb) such as alirocumab and evolocumab has demonstrated that an LDL-C reduction of 50–60% is associated with a lower rate of cardiovascular events [6, 7].”
Atherosclerosis: A Pathologist’s Perspective
Verbóová, Ľ., Nedoroščík, A., Kisková-Šimková, T., Šmirjáková, A., Bohus, P., Kollár, M., Virag, M., Mazarova, K., & Závacká, M. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13020085 · Cited by 19
Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology
Mahmood, T. A., & Shapiro, M. D. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000657 · Cited by 14
How Far We Have Come, How Far We Have Yet to Go in Atherosclerosis Research
Libby, P., & Bornfeldt, K. (2020) · Circulation Research · doi:10.1161/circresaha.120.316994 · Cited by 14
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Indraratna, P., Khasanova, E., Gulsin, G. S., Τζίμας, Γ., Takagi, H., Park, K. H., Lin, F. Y.-H., Shaw, L. J., Lee, S., Narula, J., et al. (2021) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2021.11.004 · Cited by 16
Schäfer, A., Akin, M., Diekmann, J., & König, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061509 · Cited by 17
Approach to patients with elevated low-density lipoprotein cholesterol levels
Feingold, K. R., & Chait, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101658 · Cited by 18
Cho, K. H., Kim, M. C., Choo, E. H., Choi, I. J., Lee, S. N., Park, M., Park, C. S., Kim, H.-Y., Kim, C. J., Sim, D. S., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025958 · Cited by 14
“24 28 Furthermore, in a large clinical trial, lowering of LDL-C by proprotein convertase subtilisin/kexin type 9 inhibitors was found to be equally effective in reducing cardiovascular events in patients with atherosclerotic cardiovascular disease, regardless of whether the baseline LDL-C was 70…”
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis
Zhao, X., Wu, J., & Zhu, S. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15494 · Cited by 14
“9%, respectively.(24,25) Seasonal allergies are rarely reported in clinical trials, with an incidence of approximately 1.”
BackgroundLou, B., Liu, H., Luo, Y., Jiang, G. T., Wu, H., Wang, C., Wu, Y., Zhou, B., Yuan, Z., She, J., et al. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01724-9 · Cited by 16
Heidemann, B. E., Koopal, C., van Lennep, J. E. R., Stroes, E. S. G., Riksen, N. P., Mulder, M. T., van der Zee, L. C. V. V. –., Blackhurst, D., Marais, A. D., & Visseren, F. L. J. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.006 · Cited by 15
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

